JAGX:NASDAQJaguar Health, Inc. Analysis

Jaguar Health is trading at $0.369, well below its 20‑day (≈$0.41) and 50‑day (≈$0.55) simple moving averages, signalling a persistent bearish price action. The RSI of 37 suggests modest weakness but not yet oversold, while the MACD histogram turning positive offers a faint bullish hint that could be short‑lived. With a beta near 2.8 and a 30‑day volatility exceeding 135%, the stock is extremely price‑sensitive, and the computed max drawdown of -97% underscores the downside risk.
On the fundamentals side, revenue slipped 7.8% YoY to $11.5 M, operating cash flow and free cash flow remain deeply negative, and the balance sheet shows $43.6 M of debt against under $1 M of cash. Valuation multiples are ultra‑low (price‑to‑book 0.43, price‑to‑sales 0.40) and there is no dividend, reflecting a distressed but potentially undervalued position. Recent material news – a 5% revenue uptick, a strategic partnership, FDA endorsement to extend the Crofelemer trial for MVID, and a new joint‑venture pre‑clinical study – provide possible catalysts that could reverse the downtrend if clinical milestones are met.